Jump to content

M2613

From Wikipedia, the free encyclopedia
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
M2613
Clinical data
Other namesM-2613; Methoxyethoxy-triphenylbromoethylene
Drug classNonsteroidal estrogen
Identifiers
  • 1-Bromo-2-(p-ethoxyphenyl)-2-(p-methoxyphenyl)-1-phenylethylene
CAS Number
Chemical and physical data
FormulaC23H21BrO2
Molar mass409.323 g·mol−1

M2613 is a nonsteroidal estrogen derived from triphenylbromoethylene which was studied for the treatment of breast cancer in women in the 1940s, but was never marketed.[1][2]

See also

References

  1. ^ Walpole AL, Paterson E (October 1949). "Synthetic oestrogens in mammary cancer". Lancet. 2 (6583): 783–6. doi:10.1016/s0140-6736(49)91370-7. PMID 15391512.
  2. ^ Jordan VC (February 2015). "The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer". Endocr. Relat. Cancer. 22 (1): R1–31. doi:10.1530/ERC-14-0448. PMC 4494663. PMID 25339261.